Gastrointestinal Cancer News

The FDA approved trifluridine and tipiracil for the treatment of adults with metastatic gastric or gastroesophageal junction adenocarcinoma.

In this guest commentary from the steering committee for the Collaborative Group of the Americas on Inherited Gastrointestinal Cancers (CGA-IGC), Michael Hall, MD, of Fox Chase Cancer Center, Matthew Yurgelun, MD, of the Dana-Farber Cancer Institute, Swati Patel, MD, of the University of Colorado, and Heather Hampel, MS, LGC, of the Ohio State University Medical Center, address the need for greater physician awareness amidst the growing uptake of direct-to-consumer genetic testing that may or may not indicate an increased risk for certain gastrointestinal and other cancers. CGA-IGC is a clinical research group focused on hereditary GI cancers. It supports greater access to genetic testing, but with guidelines and research necessary to comprehend the downstream impact.

The Royal Swedish Academy of Sciences presented Dennis J. Slamon, MD, and Brian J. Druker, MD, with the 2019 Sjöberg Prize.

Three members of the faculty at City of Hope received awards in recognition of their contributions to the field of oncology.

HIV seropositivity appeared associated with shorter OS among patients with hepatocellular carcinoma despite sufficient antiretroviral treatment, according to results of a global multicohort study published in Journal of Clinical Oncology.

Excess body weight is responsible for at least one in 17 new cancers in each state in the U.S., according to a study published in JAMA Oncology.

Increased intake of whole grains correlated with a reduced risk for hepatocellular carcinoma among adults regardless of cancer etiology, according to study results published in JAMA Oncology.

Rivaroxaban led to substantially lower incidence of venous thromboembolism and death of VTE among ambulatory patients with cancer death during the treatment intervention, according to results of the phase 3b randomized trial CASSINI published in The New England Journal of Medicine.

Overall cancer death rates are dropping faster among black Americans than white Americans, according to a report published in CA: A Cancer Journal for Clinicians.

The addition of pembrolizumab to best supportive care failed to extend survival among patients with advanced hepatocellular carcinoma who received prior systemic therapy, according to study results released by the agent’s manufacturer.